Comparison of MPC-6827 activity in xenograft models with different dosing schedules.

J. T. Jones,Vijay Baichwal,Leslie Reeves,Chad Bradford,Damon I. Papac,Kenton Zavitz,Andrew P. Beelen,Gary Mather,Robert O. Carlson

Comparison of MPC-6827 activity in xenograft models with different dosing schedules.

2011

J. T. Jones
Vijay Baichwal
Leslie Reeves
Chad Bradford
Damon I. Papac
Kenton Zavitz
Andrew P. Beelen
Gary Mather
Robert O. Carlson

e13080 Background: MPC-6827 is a small molecule microtubule disrupting agent that is being evaluated in phase II studies for the treatment of glioblastoma multiforme. It crosses the blood-brain bar...

Keywords:

Schedule
Dosing
Physical therapy
Medicine
Pharmacology
Internal medicine
dosing schedules
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations